Dexamethasone intraocular injection - EyePoint Pharmaceuticals

Drug Profile

Dexamethasone intraocular injection - EyePoint Pharmaceuticals

Alternative Names: DEXYCU; IBI-10090

Latest Information Update: 16 Apr 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Icon Bioscience
  • Developer EyePoint Pharmaceuticals
  • Class Anti-inflammatories; Antiemetics; Antineoplastics; Fluorinated steroids; Glucocorticoids; Pregnadienetriols; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Registered Ocular inflammation

Most Recent Events

  • 13 Apr 2018 EyePoint Pharmaceuticals receives patent allowance for two patents related to dexamethasone intraocular injection in USA
  • 28 Mar 2018 Icon Bioscience has been acquired by EyePoint Pharmaceuticals
  • 28 Mar 2018 EyePoint Pharmaceuticals announces intention to launch dexamethasone intraocular injection in the first half of 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top